P-20: How Can Russia Join the List of Attractive Countries for Investment?
Investment in advanced scientific research and pharmaceutical manufacturing could create an important stimulus for the development of the Russian economy. Worldwide, pharmaceutical companies are investing around USD 140 billion in R&D annually. In order to join the list of countries considered to be attractive from an investment point of view by the pharmaceutical industry (the Biopharmaceutical Competitiveness and Investment Survey), the following criteria must be fulfilled: a stable economy, favourable legislation and tax regulations, a high concentration of intellectual resources, a good medical and pharmaceutical education system, and a highly productive workforce. To date, Russia has yet to be ranked among the top 20 in the survey. What measures can be taken to enable Russia to join the list of the most attractive countries for pharmaceutical investment? How can the priorities of Russia’s Scientific and Technological Development Strategy be realized in the areas of high-tech healthcare and pharmaceuticals? What barriers need to be overcome in state regulation of the pharmaceuticals market in order to expand access to medicines and increase investment attractiveness? How can more effective outcomes from scientific research in Russia be achieved?